Megakaryocyte Heterogeneity in Sickle Cell Disease
ConditionSickle Cell Disease (SCD)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de la Guadeloupe
About this trial
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow.
The main aim of this study is to characterize the distribution of the different megakaryocyte subpopulations of sickle cell disease patients SS and SC and in particular the "immune" megakaryocytes CD148+CD48+ and to compare it with the platelet phenotype.
Eligibility criteria
Qualifiers
patients with SS or SC SCD
diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
patients older than 18 years at inclusion
clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months)
Disqualifiers
patients younger than 18 years old
patients with hemoglobinopathy other than SS and SC SCD
patients with a transfusion therapy or on bleeding therapy for less than three months
patients no affiliated to national social security
Trial design
Treatments tested in this trial
- Not listed
Trial groups
100 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov